The Next Phase Of The Obesity Drug Race

Five years after Wegovy's FDA approval, the obesity-drug market has shifted quickly as Novo Nordisk and Eli Lilly launched GLP-1 pills this year. Emerging competitors including Structure Therapeutics and Zealand Pharma are also vying for share, pointing to intensifying competition in a fast-growing therapy area. The article is largely descriptive and signals ongoing innovation rather than a specific catalyst.

Analysis

Five years after Wegovy's FDA approval, the obesity-drug market has shifted quickly as Novo Nordisk and Eli Lilly launched GLP-1 pills this year. Emerging competitors including Structure Therapeutics and Zealand Pharma are also vying for share, pointing to intensifying competition in a fast-growing therapy area. The article is largely descriptive and signals ongoing innovation rather than a specific catalyst.